The heparanase inhibitor, SST0001, was shown to inhibit tumor cell proliferation and to decrease VEGF, HGF and MMP-9 levels in multiple myeloma [341], to abolish the increased pancreatic cancer cell invasion dependent on radiotherapy-induced heparanase level [342], and to delay sarcoma tumor growth (when administered alone), or even induce a complete regression (in 5 out of 8 mice), when administered in combination with Irinotecan [343]. Here, HPSE is linked to familial pancreatic carcinoma.